| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/20/2002 | EP1180164A2 Methods using of fab i and compounds modulating fab i activity |
| 02/20/2002 | EP1180159A1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| 02/20/2002 | EP1180151A2 Protein kinases |
| 02/20/2002 | EP1180146A1 Secreted alpha-helical protein - 32 |
| 02/20/2002 | EP1180144A2 Cytoskeleton-associated proteins |
| 02/20/2002 | EP1180143A2 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 02/20/2002 | EP1180141A2 The p2x 3 receptor, methods of altering p2x 3receptor activity and uses thereof |
| 02/20/2002 | EP1180140A1 Variants of traf2 which act as an inhibitor of tnf-alpha signaling pathway |
| 02/20/2002 | EP1180122A1 Structural models for cytoplasmic domains of transmembrane receptors |
| 02/20/2002 | EP1180116A2 Fap-activated anti-tumor compounds |
| 02/20/2002 | EP1180099A1 New compounds |
| 02/20/2002 | EP1180098A1 New compounds |
| 02/20/2002 | EP1180058A1 Combinations of gaba analogs and tricyclic compounds to treat depression |
| 02/20/2002 | EP1180053A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy |
| 02/20/2002 | EP1180039A2 Factor for regulation of neurite growth |
| 02/20/2002 | EP1180038A2 Antifungal combination use |
| 02/20/2002 | EP1180037A2 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
| 02/20/2002 | EP1180026A2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 02/20/2002 | EP1180018A1 Preparations for the application of anti-inflammatory agents |
| 02/20/2002 | EP1041896B1 Fat blend |
| 02/20/2002 | EP1028707B1 Sustained release ophthalmic compositions containing water soluble medicaments |
| 02/20/2002 | EP0772441B1 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
| 02/20/2002 | EP0567613B1 Compositions for therapy and prevention of cancer |
| 02/20/2002 | CN1336934A Bis-amino acid sulfonamides containing N-terminally a substituted benzyl group as HIV protease inhibitors |
| 02/20/2002 | CN1336828A Composition and method for the enhancement of the efficacy of drugs |
| 02/20/2002 | CN1336819A Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 02/19/2002 | US6348602 Cyclic AMP-specific phosphodiesterase inhibitors |
| 02/19/2002 | US6348582 Prokaryotic polynucleotides polypeptides and their uses |
| 02/19/2002 | US6348579 FtsL |
| 02/19/2002 | US6348578 Apt |
| 02/19/2002 | US6348508 Method for treating dry eye |
| 02/19/2002 | US6348506 Treatment of fibromyalgia with ubiquinone 10 and succinic acid |
| 02/19/2002 | US6348501 Lotions with carriers, capsaicin, lavender oil, myristal myristate |
| 02/19/2002 | US6348486 Methods for modulating bladder function |
| 02/19/2002 | US6348481 Pharmaceutical composition for angiotensin II-mediated diseases |
| 02/19/2002 | US6348476 Ion exchange inhibitor for cardiovascular disorders |
| 02/19/2002 | US6348451 Acyl deoxyribonucleoside derivatives and uses thereof |
| 02/19/2002 | US6348342 Compounds |
| 02/19/2002 | US6348340 Compounds |
| 02/19/2002 | US6348209 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm |
| 02/19/2002 | US6348207 Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and form orally deliverable supramolecular complex, orally administering complex to subject |
| 02/19/2002 | US6348194 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 02/19/2002 | US6347633 Treatment of hepatitis C using hyperthermia |
| 02/19/2002 | CA2195065C Inhalation composition |
| 02/19/2002 | CA2182030C Use of a bradykinin antagonist in a cosmetic, pharmaceutical or dermatological composition; composition thus obtained |
| 02/19/2002 | CA2023630C Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
| 02/18/2002 | CA2355411A1 Combination therapy using sympathetic nervous system antagonists and endothelin antagonists |
| 02/18/2002 | CA2354653A1 Peptide mutant of human erab/hadh2, its x-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 02/16/2002 | CA2354639A1 Method of making tablets and tablet compositions produced therefrom |
| 02/14/2002 | WO2002012900A1 Identification of viral agents in breast ducts and antiviral therapy therefore |
| 02/14/2002 | WO2002012565A1 Association of sim2 with cancer |
| 02/14/2002 | WO2002012502A2 Anti-tnf antibodies, compositions, methods and uses |
| 02/14/2002 | WO2002012501A2 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/14/2002 | WO2002012500A2 Anti-il-12 antibodies, compositions, methods and uses |
| 02/14/2002 | WO2002012467A2 Drug metabolizing enzymes |
| 02/14/2002 | WO2002012461A2 Regulation of human membrane-type serine protease |
| 02/14/2002 | WO2002012448A1 Methods for culturing human lung mast cells and uses thereof |
| 02/14/2002 | WO2002012421A1 Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 02/14/2002 | WO2002012347A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | WO2002012340A2 Transporters and ion channels |
| 02/14/2002 | WO2002012339A2 Sequences for integrin alpha-8 |
| 02/14/2002 | WO2002012326A2 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | WO2002012325A2 Suppressor gene |
| 02/14/2002 | WO2002012286A2 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | WO2002012275A2 Lat peptides and their use in assays for identifying immunosuppressants |
| 02/14/2002 | WO2002012266A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 02/14/2002 | WO2002012265A1 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| 02/14/2002 | WO2002012263A1 Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses |
| 02/14/2002 | WO2002012240A1 Derivatives of variolin b |
| 02/14/2002 | WO2002012224A2 Bicyclic compounds as h3 receptor ligands |
| 02/14/2002 | WO2002012214A2 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 02/14/2002 | WO2002012196A2 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | WO2002012190A2 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/14/2002 | WO2002012178A1 Compounds acting as melanocortin receptor ligands |
| 02/14/2002 | WO2002011779A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | WO2002011770A1 Compositions for preventing urinary calculus |
| 02/14/2002 | WO2002011769A1 Vascular endothelial growth factor 2 |
| 02/14/2002 | WO2002011768A1 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 02/14/2002 | WO2002011767A2 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
| 02/14/2002 | WO2002011766A2 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 02/14/2002 | WO2002011765A1 COMBINATION PREPARATION WITH AN ERβ SELECTIVE ESTROGEN AND A SERM OR ANTIESTROGEN |
| 02/14/2002 | WO2002011764A2 Pharmaceutical compositions |
| 02/14/2002 | WO2002011763A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | WO2002011744A1 A strong antioxidant composite capsule containing grape seed extract opc and process for producing the same |
| 02/14/2002 | WO2002011743A2 Treatment of prostate cancer |
| 02/14/2002 | WO2002011742A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/14/2002 | WO2002011741A1 Cardioplegic solution |
| 02/14/2002 | WO2002011739A1 Methods for preventing pressure induced apoptotic neural cell death |
| 02/14/2002 | WO2002011735A2 Association of a purine activity and a nonsteroidal anti-inflammatory anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011728A2 Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/14/2002 | WO2002011719A2 Lipase inhibitors for the treatment of dyspepsia |
| 02/14/2002 | WO2002011716A2 Liquid formulation of metformin |
| 02/14/2002 | WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | WO2002011711A2 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 02/14/2002 | WO2002011710A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | WO2002011708A2 Methods for inducing apolipoprotein e secretion |
| 02/14/2002 | WO2002011705A2 Composition for combined use of aromatase inhibitors |
| 02/14/2002 | WO2002011704A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | WO2002011703A1 Hybrid neuroprosthesis for the treatment of brain disorders |
| 02/14/2002 | WO2002011683A1 Topical gel delivery system |